Hygroton (Chlortalidone)

Chlortalidone inhibits the Na⁺‑Cl⁻ symporter in the distal convoluted tubule of the kidney, decreasing reabsorption of sodium and chloride. This leads to increased urinary loss of sodium, chloride, and water, reducing plasma volume and peripheral resistance, which together lower blood pressure and alleviate fluid retention.

The dosage of Hygroton is individualized by the prescribing clinician based on the patient’s medical condition, response to therapy, and renal function. The prescriber determines the appropriate strength and frequency, and patients should follow the written prescription without alteration.

Safety of chlortalidone in pregnancy and lactation has not been definitively established. It is generally classified as a category where benefits must outweigh potential risks, and it should only be used if clearly needed under medical supervision. Breastfeeding mothers should consult their healthcare provider before use.

To request Hygroton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with classic thiazide diuretics such as hydrochlorothiazide, chlortalidone has a longer half‑life and more potent natriuretic effect, often providing better blood‑pressure control in resistant cases. However, its longer duration may increase the risk of electrolyte disturbances, so monitoring is essential.

Hygroton should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its potency and prevents degradation.

Hygroton is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and whether to split doses. Consistent daily intake helps achieve stable blood‑pressure control.

The most serious risks include severe dehydration, marked electrolyte imbalances such as hyponatremia or hypokalemia, gout attacks, pancreatitis, and rare blood disorders like agranulocytosis. Patients should be educated to recognize symptoms such as extreme weakness, muscle cramps, abdominal pain, or unusual bruising and seek medical attention promptly.

Hygroton is contraindicated in patients with anuria, severe renal impairment, known hypersensitivity to chlortalidone, or those with uncontrolled gout. Caution is also advised for individuals with hepatic disease, electrolyte disturbances, or those taking interacting medications. Clinicians must evaluate each patient’s medical history before initiating therapy.